Piper Jaffray Companies cut shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) from an overweight rating to a neutral rating in a report released on Thursday morning, Marketbeat Ratings reports.
A number of other equities analysts also recently issued reports on the stock. SunTrust Banks, Inc. set a $136.00 price objective on shares of Zimmer Biomet Holdings and gave the company a buy rating in a research note on Wednesday. Zacks Investment Research upgraded shares of Zimmer Biomet Holdings from a sell rating to a hold rating in a research note on Tuesday, September 26th. Gabelli initiated coverage on shares of Zimmer Biomet Holdings in a research note on Thursday, August 24th. They issued a buy rating and a $142.00 target price for the company. Oppenheimer Holdings, Inc. set a $137.00 target price on shares of Zimmer Biomet Holdings and gave the company a buy rating in a research note on Monday, August 14th. Finally, BidaskClub downgraded shares of Zimmer Biomet Holdings from a hold rating to a sell rating in a research note on Tuesday, August 1st. Three investment analysts have rated the stock with a sell rating, nine have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of Hold and a consensus target price of $134.75.
Zimmer Biomet Holdings (ZBH) opened at $109.25 on Thursday. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.80 and a current ratio of 1.47. Zimmer Biomet Holdings has a one year low of $95.63 and a one year high of $133.49. The stock has a market cap of $22,089.91, a P/E ratio of 13.54, a PEG ratio of 1.48 and a beta of 1.17.
Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.74 by ($0.02). Zimmer Biomet Holdings had a net margin of 8.36% and a return on equity of 16.29%. The business had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. During the same quarter in the prior year, the business posted $1.79 earnings per share. Zimmer Biomet Holdings’s revenue for the quarter was down .8% on a year-over-year basis. analysts predict that Zimmer Biomet Holdings will post 8.04 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this piece can be read at https://www.com-unik.info/2017/11/05/zimmer-biomet-holdings-inc-zbh-downgraded-by-piper-jaffray-companies.html.
The firm also recently announced a quarterly dividend, which was paid on Friday, October 27th. Investors of record on Friday, September 22nd were issued a dividend of $0.24 per share. The ex-dividend date of this dividend was Thursday, September 21st. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 30.19%.
Several institutional investors have recently modified their holdings of ZBH. BlackRock Inc. raised its holdings in shares of Zimmer Biomet Holdings by 4,042.4% during the first quarter. BlackRock Inc. now owns 16,740,383 shares of the medical equipment provider’s stock worth $2,044,168,000 after purchasing an additional 16,336,262 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Zimmer Biomet Holdings by 92.7% in the second quarter. JPMorgan Chase & Co. now owns 3,279,951 shares of the medical equipment provider’s stock valued at $421,146,000 after buying an additional 1,577,874 shares in the last quarter. Harbour Capital Advisors LLC increased its holdings in Zimmer Biomet Holdings by 13,131.3% in the second quarter. Harbour Capital Advisors LLC now owns 1,302,618 shares of the medical equipment provider’s stock valued at $10,145,000 after buying an additional 1,292,773 shares in the last quarter. Longview Partners Guernsey LTD increased its holdings in Zimmer Biomet Holdings by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock valued at $878,958,000 after buying an additional 1,128,973 shares in the last quarter. Finally, Koch Industries Inc. increased its holdings in Zimmer Biomet Holdings by 49,697.3% in the second quarter. Koch Industries Inc. now owns 1,040,764 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,038,674 shares in the last quarter. 85.26% of the stock is owned by hedge funds and other institutional investors.
Zimmer Biomet Holdings Company Profile
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
What are top analysts saying about Zimmer Biomet Holdings Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Zimmer Biomet Holdings Inc. and related companies.